| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() Vivelle-Dot Available In The U.S. For Menopause Symptoms MIAMI, FL -- May 10, 1999 -- Novogyne Pharmaceuticals’ Vivelle-Dot(TM) (estradiol transdermal system), the world's smallest transdermal estrogen delivery system, has been launched in the United States for use in the treatment of the symptoms of menopause. Like the original Vivelle(R) (estradiol transdermal system), Vivelle-Dot is available in four dosage strengths (.0375, .05, .075 and .10 mg/day), and provides prescribing physicians with broad dosing flexibility. In the most commonly prescribed dosage strength (.05 mg/day), Vivelle-Dot is about the size and thickness of a postage stamp. By area, it is about one-third the size of Berlex’s Climara(R) and about one-quarter the size of Novartis’ Estraderm(R), the current U.S. market leaders. The new patch utilises Noven's proprietary Dot Matrix(TM) adhesive technology and delivers 17(beta)-estradiol through the skin and into the bloodstream. 17(beta)-estradiol is identical to a woman's own estrogen, unlike those estrogen therapies derived from equine sources. In the U.S., more than 40 million women are in the menopausal age range (between 45 and 59), and every 16 seconds another woman enters her 50s.
|